Biodexa Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Biodexa Pharmaceuticals has a total shareholder equity of £8.7M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £14.0M and £5.2M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£5.06m |
| Equity | UK£8.73m |
| Total liabilities | UK£5.24m |
| Total assets | UK£13.97m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 5MP1's short term assets (£7.5M) exceed its short term liabilities (£3.5M).
Long Term Liabilities: 5MP1's short term assets (£7.5M) exceed its long term liabilities (£1.8M).
Debt to Equity History and Analysis
Debt Level: 5MP1 is debt free.
Reducing Debt: 5MP1 has no debt compared to 5 years ago when its debt to equity ratio was 4.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 5MP1 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 5MP1 is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.